European antitrust regulators have allowed manufacturers of generic drugs to unite for the supply of medicines in clinics for the treatment of patients with coronavirus. About it reports Reuters.
This measure was the final step in the direction of simplification the strict Antimonopoly regulation in the EU, which should help in the fight against the pandemic. Regulators said that the rejection of the previously approved rules will allow to avoid deficiency of essential generic drugs.
“In the current environment, a temporary partnership of pharmaceutical companies seems to be justified”, – reads the statement of the regulators.